Cell and gene-based therapies represent a novel therapeutic modality that has the potential to provide a treatment option for a range of medical conditions. There are, however, numerous processing and manufacturing challenges that must be addressed before such therapies are considered commercially and clinically viable. A significant challenge associated with the manufacture of such therapies is ensuring cell quality and the product's critical quality attributes are retained throughout the entire bioprocess. Biopreservation is an important aspect of cell and gene-based therapy bioprocessing, which enables the development of cell banks. It increases process flexibility by providing a shelf-life to the product, enables the storage of intermediates and provides breakpoints within the process. In this article, we summarize the advances and challenges associated with biopreservation of cell and gene therapies.
Cell and gene-based therapies (CGTs) represent a novel therapeutic modality that have the potential to address the significant medical challenges associated with chronic, age-related clinical indications and provide a treatment option for a range of unmet medical needs. There are, however, numerous processing and manufacturing challenges that must be addressed before such therapies are considered commercially and clinically viable. A significant challenge associated with the manufacture of such therapies is ensuring cell quality and that the product's critical quality attributes (CQAs) [1] are retained throughout the entire bioprocess, from initial cell isolation through to delivery and administration to a patient. Unlike traditional biopharmaceutical manufacture, manufacturing paradigms for CGTs may involve an autologous (patient-specific), allogeneic (universal donor) or haplobank approach.
An important aspect of all CGT bioprocessing is biopreservation. This enables the creation of cell banks (master and working cell banks for allogeneic product manufacture or storage banks for patient specific material such as cord blood). This can uncouple the expansion and/or manipulation of cells from the clinic, creating product shelf-life and also facilitates the transport/storage of any product intermediates (e.g., newly isolated cells or even viral vectors) (Figure 1) [2]. Indeed, where the process necessitates transfer of cellular material from the clinic to an off-site facility for processing and/or expansion, biopreservation measures will be critical to product quality and success. This places particular emphasis on the appropriate selection of biopreservation methods, with a need to demonstrate that they do not adversely impact the product's CQAs. Moreover, the biopreservation methodology needs to align with the business and distribution model to ensure commercial success and should occur during early stages of development given the integral role biopreservation plays in the logistical and manufacturing bioprocessing considerations 
Cell isolation Manipulation
The manipulation indicated would vary from therapy to therapy or may not be needed but could for example include differentiation of iPSC cells to cells of therapeutic interest, genetic engineering of T-cells for CAR T cells production. For the creation of cell banks, be it master cell banks for allogeneic products or single vials of patient specific material stored for later use, cryopreservation is the most commonly used option. However, hypothermic storage at ambient or refrigerated temperatures may enable short shelf lives of some 'fresh' products to be achieved.
Biopreservation also determines the level of at-clinic processing, that is, will the cells need to be thawed prior to administration or are they preserved and subsequently delivered at ambient temperature. Thus, in many CGT processes, it is likely that biological material will require at least one biopreservation step, if not more (Figure 1 ). This will be exacerbated for gene therapy products where other biological material (such as viral vectors) are also likely to undergo an independent preservation process prior to their addition to the cellular material.
TYPES OF BIOPRESERVATION
Biopreservation is often used synonymously with cryopreservation. However, whilst a review of the regulatory submissions for mesenchymal stem cell therapies to the FDA in 2012 reveals that freezing is certainly a key biopreservation method, with more than 80% of submissions involving a frozen product [4], it is not the only biopreservation method that is being considered for commercial and clinical use. Indeed, given the need to retain the product CQAs and that multiple different manufacturing/distribution models are likely to be employed for CGTs (e.g., autologous, allogeneic and haplobank), it has become increasingly important to consider other types of biopreservation for the storage and transportation of biological material. This includes hypothermic preservation (i.e., 'cell pausing') at either ambient [5] [6] [7] or refrigerated chilled temperatures [8,9]. Ultimately, the decision as to which biopreservation method is most appropriate will need to take into account which method has the least effect on the product's CQAs whilst remaining both commercially, clinically and logistically viable.
Cryopreservation
Freezing is the most common biopreservation method employed in CGT processes [ François et al. one of the groups who reported that hMSCs were adversely impacted by cryopreservation did note that thawed hMSCs recovered their immunomodulatory functionality 24 hours post-culture [20] suggesting that a cell-recovery process may need to be incorporated post-thaw to retain viability and, more importantly, ensure functionality of the cryopreserved cells. If indeed this is necessary for the product to retain its CQAs, this increases process complexity and costs, with a particular consideration as to where the cell-recovery process step is conducted. Moreover, the differences between the aforementioned studies could also potentially be explained by differences in the cell handling, cryopreservation medium formulations, freezing protocols and thawing procedures. That the thawing process is often badly, if at all, controlled and that this may be responsible for some of the damage perceived to be caused by cryopreservation is now starting to be recognised by the community. For example, at ISCT 2017, one report highlighted the interplay between cooling rate and thawing rate for T cell recovery post-thaw [24]. To address this, rapid and specialised thawing devices are being developed such as the ThawSTAR® from Medcision and VIA Thaw by Asymptote.
As well as CRF, vitrification can also be used to cryopreserve cells. This involves the rapid cooling of the cellular material, thereby avoiding formation of both extra-and intra-cellular ice crystals [25] and generating amorphous ice. Although vitrification has been employed successfully for multiple cell types, in particular, colonies of human embryonic stem cells, where vitrification has resulted in high levels of viability and retention of functionality post-thaw [26-28]. However, this method uses significantly higher levels of cryoprotective agent (CPA) than in CRF to prevent ice crystallisation, and enable vitrification at a higher glass transition temperature and an achievable cooling rate. Also, although efforts are ongoing to generate larger scale vitrification methods, the high cooling rates needed mean that only small volumes (typically 1-20 µl) may be vitrified at once [3], making this a poor option for the freezing of cell therapies currently.
Cryopreservation challenges
Although cryopreservation is currently considered to be the industry standard for CGT biopreservation, there are numerous challenges and considerations. Primarily, it is critical to understand the implications of cryopreservation on the product's CQAs. This requires in-depth understanding about the product's biological attributes, mechanism of action and safety profile. There are also concerns with the use of liquid nitrogen in a GMP environment, where it may compromise clean room air quality given the potential for contamination with microorganisms, particulates and debris during transport and storage The most significant concern with cryopreservation is the use of CPAs, in particular the intracellular CPA, dimethyl sulphoxide (DMSO). DMSO, the most commonly used CPA, is classified by the FDA as a class 3 solvent [33] and is considered to be toxic to both cells and patients at room temperature . It is recommended that patients do not receive more than 1 g/kg body weight/day of DMSO, with a maximum permissible limit of 50 mg/day [34, 35] . Such concerns and restrictions have been put in place due to the toxicology issues associated with DMSO [36] . This concern is exacerbated with vitrification, given the need to significantly increase the CPA concentrations to avoid ice crystal formation. Although DMSO is still the most commonly used CPA, alternatives are being considered for the cryopreservation of mammalian cells that pose a lower toxicity risk including trehalose [37] and sucrose [38] . These CPAs provide a similar level of protection to cellular material during freezing but the challenge with these CPAs is their inability to penetrate the cell. The delivery of these CPAs into mammalian cells requires an additional process step, such as electroporation or permeabilization [37, 39, 40] . Such procedures alone can lead to cell death and destruction.
Hypothermic storage
Whilst it is generally recognised and accepted that for long-term storage (months/years), cryopreservation remains the most cost-effective and scientifically robust method, there are genuine concerns about the use of cryopreservation for short-term storage and transport due to the potential for ice crystal formation and potentially toxic CPA concentrations. A potential alternative biopreservation method that is amenable for shortterm requirements (e.g., days) is hypothermic storage. This includes chilled preservation, a process where the temperature is reduced to 2-8˚C and ambient preservation (room temperature). Refrigerated preservation is currently used for the transfusion of red blood cells for the treatment of severe anaemia. Red blood cells can be stored at refrigeration temperature for up to 42 days within an additive solution, where they can then be transported to the site of administration upon request [41] . Moreover, refrigeration temperatures have also been used for the storage and transportation or whole organs prior to transplantation [42, 43] .
Much of the research and development activity for chilled preservation relates to storage and transportation of whole organs and red blood cells. However, with the increasing promise of CGTs, there has been renewed interest in shortterm chilled preservation for CGT cell candidates, in particular, stem cells. The commercial hypothermic preservation medium solution HypoThermosol® Free Radical Solution (HTS-FRS) (BioLife Solutions, USA) has been used for the successful storage and preservation of a range of cell types including hMSCs [44] and differentiated human neural stem cells [45] . In the case of hMSCs, the cells retained greater than 85% viability after 96 hours when stored at 4˚C [44] , and for the differentiated human neural stem cells, the cells were seeded onto cellular collagen constructs and placed into a range of different medium compositions for storage at 4˚C for 48 h. The cells which were preserved in the HTS-FRS medium composition demonstrated the least cell death (<10%), even lower than cells which were preserved using DMSO under cryogenic conditions [45] . Indeed, recently, HTS-FRS was used for TiGenix's Phase 1 clinical trial where expanded allogeneic adipose-derived stem cells stored in HTS-FRS were administered to pa-
Although chilled preservation will not be used as a long-term biopreservation method, it has demonstrated significant potential for its ability to suitably preserve cells at refrigerated temperatures for time periods accounting for transportation across countries. Transporting a CGT product between countries a significant distance apart can take up to 24 h, however this does not take into account transportation delays, customs checks and potential clinical complications. As such, the longer the cells can be shown to demonstrate the retention of their CQAs in the biopreservation formulation, the more flexibility this provides to the overall process [3]. The additional advantage of this type of preservation in comparison to cryopreservation is that much of the clinical infrastructure, logistics and supply chain aspects to enable chilled storage and transportation is already in place. As such, significant changes to current practice and facilities will unlikely be required.
Ambient temperature preservation simplifies the process even further compared to chilled preservation and does not require any additional infrastructure to maintain refrigerated or cryogenic temperatures, thereby reducing cost and process complexity. Unlike cryopreservation and, to a lesser extent, chilled preservation, the research with ambient temperature preservation is not as extensive and has only become an area of interest in light of the potential advantages this preservation method confers over the aforementioned techniques. The potential of this technique is demonstrated by Chen et al. (2013) who demonstrated that they were able to store hMSCs and mouse embryonic stem cells inside alginate hydrogels for 5 days in ambient conditions in an air-tight environment. Cell viability post-preservation was found to be 80% and 74% for the hMSCs and mouse embryonic stem cells, respectively [47] . Similarly, Swioklo et al., showed human adipose-derived stem cells could be encapsulated and stored at a range of temperatures, from 4-23°C, although 15°C was found to be the optimum [48] . The disadvantage to this method, however, is the need for a cell retrieval step which increases process complexity and will likely need to be undertaken at or near clinic. Ambient temperature cell preservation has also been reported for hair follicles which demonstrated adequate graft recovery post-preservation [49] . Additionally, Hunt et al., have reported the successful preservation of other mammalian cell types (CHO and HEK293 cells) at temperatures ranging between 6-24˚C for more than 3 days [6].
As with chilled preservation, ambient temperature preservation is a potential technique that can be used for pooling of cells during the process (for example post-harvest from culture devices awaiting downstream processing), or indeed, used for storage and transportation to site of clinical administration. However, it is critical that the acceptable temperature ranges and timeframes are identified and validated, with the validated conditions making allowances for potential processing and/ or transport delays. There should also be consideration of effect of multiple preservation steps (if employed) during a process and the cumulative effect of ambient temperature preservation throughout the process. Greater product and process understanding will facilitate the consideration of multiple processing options and increase overall process flexibility.
Hypothermic preservation challenges
There are two key challenges for chilled preservation. The first has been alluded to previously and relates to the maximum time-period it can be effectively used, and importantly, validated, as a biopreservation method. Although there has been promising research data that suggest chilled preservation in conjunction with specifically designed hypothermic medium preservation solutions can retain cell viability and functionality across multiple days, there is a greater burden of evidence required for validation.
The other key challenge with chilled preservation, and exacerbated for ambient preservation (discussed later), is the fact that chilled preservation only slows and does not arrest cellular functions, activity and metabolism. This results in the potential build-up of deleterious metabolites and, perhaps more critically, the depletion of important substrates required for cell maintenance [50, 51] . It should also be noted that although chilled preservation does not result in cellular damage arising from ice crystal formation or suffer from CPA toxicity issues experienced with cryopreservation, there are concerns about chilled preservation resulting in cold-induced cell damage [52] . This risk of cell damage is intrinsically linked to the preservation time, with a greater risk of cell damage and decreased viability with longer preservation times [3]. There are also concerns with chilled preservation that once rewarmed to the appropriate administration temperature, the increased production of free radicals and other deleterious metabolites may result in delayed-onset cell death, which may not be noticeable immediately but take hours or days to become apparent [53] .
A key challenge with ambient temperature preservation is demonstrating the utility and efficacy of such a preservation at industrial scales and practical terms. Given the relative infancy of this area of research, it is expected that further studies will be conducted outlining the promise and potential of this technique. However, at present, there is little that has been conducted with relevant cell types with a focus on CGT manufacture and bioprocessing to be able to make a strong scientific case for ambient temperature preservation. However, should it be scientifically feasible, the advantages of ambient temperature preservation are substantial and would significantly reduce process, storage and transportation costs.
TRANSLATIONAL INSIGHT
Biopreservation of biological material for CGTs is often considered too late in process development or not given due attention because of what is often perceived as other, 'more important' development activities. However, for effective CGT process development, given its pivotal role in process development, storage, transportation and overall business model, it is critical to identify early in process development which biopreservation technique(s) (cryo-, chilled, or ambient preservation) is the most appropriate for the CGT. Cryopreservation will remain the only feasible biopreservation technique for long-term storage (months/years); however, both chilled and ambient preservation methods provide additional process flexibility, particularly with respect to interprocess pooling/storage and transportation across manufacturing and clinical facilities. As with any CGT process, it is unlikely that a universal biopreservation approach will be appropriate for all cases and ultimately the process needs to be determined after thorough development activity to identify effects of biopreservation on the product's CQAs and the implications of the technique on the distribution and commercial models. 
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